WO2004039829A3 - Use of cpg oligonucleotides in the treatment of hepatitis c virus infection - Google Patents

Use of cpg oligonucleotides in the treatment of hepatitis c virus infection Download PDF

Info

Publication number
WO2004039829A3
WO2004039829A3 PCT/IB2003/005520 IB0305520W WO2004039829A3 WO 2004039829 A3 WO2004039829 A3 WO 2004039829A3 IB 0305520 W IB0305520 W IB 0305520W WO 2004039829 A3 WO2004039829 A3 WO 2004039829A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
treatment
virus infection
cpg oligonucleotides
subjects
Prior art date
Application number
PCT/IB2003/005520
Other languages
French (fr)
Other versions
WO2004039829A2 (en
Inventor
Navneet K Ahluwalia
Susan M Efler
Heather L Davis
Joerg Vollmer
Original Assignee
Coley Pharmaceutical Group Ltd
Coley Pharm Gmbh
Navneet K Ahluwalia
Susan M Efler
Heather L Davis
Joerg Vollmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA05004588A priority Critical patent/MXPA05004588A/en
Priority to US10/532,746 priority patent/US7998492B2/en
Priority to BR0315810-1A priority patent/BR0315810A/en
Priority to AU2003283647A priority patent/AU2003283647B2/en
Priority to CA002503693A priority patent/CA2503693A1/en
Priority to EP03775627A priority patent/EP1556077A2/en
Priority to JP2004547932A priority patent/JP2006515277A/en
Priority to EA200500733A priority patent/EA008777B1/en
Application filed by Coley Pharmaceutical Group Ltd, Coley Pharm Gmbh, Navneet K Ahluwalia, Susan M Efler, Heather L Davis, Joerg Vollmer filed Critical Coley Pharmaceutical Group Ltd
Priority to NZ540098A priority patent/NZ540098A/en
Publication of WO2004039829A2 publication Critical patent/WO2004039829A2/en
Publication of WO2004039829A3 publication Critical patent/WO2004039829A3/en
Priority to US11/183,253 priority patent/US20060003962A1/en
Priority to AU2010203015A priority patent/AU2010203015B2/en
Priority to US12/946,806 priority patent/US20110135605A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Abstract

The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.
PCT/IB2003/005520 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection WO2004039829A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2004547932A JP2006515277A (en) 2002-10-29 2003-10-29 Methods and products for treatment and prevention of hepatitis C virus infection
BR0315810-1A BR0315810A (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
AU2003283647A AU2003283647B2 (en) 2002-10-29 2003-10-29 Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA002503693A CA2503693A1 (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP03775627A EP1556077A2 (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
MXPA05004588A MXPA05004588A (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
EA200500733A EA008777B1 (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
US10/532,746 US7998492B2 (en) 2002-10-29 2003-10-29 Methods and products related to treatment and prevention of hepatitis C virus infection
NZ540098A NZ540098A (en) 2002-10-29 2003-10-29 Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US11/183,253 US20060003962A1 (en) 2002-10-29 2005-07-15 Methods and products related to treatment and prevention of hepatitis C virus infection
AU2010203015A AU2010203015B2 (en) 2002-10-29 2010-07-15 Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US12/946,806 US20110135605A1 (en) 2002-10-29 2010-11-15 Methods and products related to treatment and prevention of hepatitis c virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42198702P 2002-10-29 2002-10-29
US60/421,987 2002-10-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10532746 A-371-Of-International 2003-10-29
US11/183,253 Continuation US20060003962A1 (en) 2002-10-29 2005-07-15 Methods and products related to treatment and prevention of hepatitis C virus infection
US12/946,806 Continuation US20110135605A1 (en) 2002-10-29 2010-11-15 Methods and products related to treatment and prevention of hepatitis c virus infection

Publications (2)

Publication Number Publication Date
WO2004039829A2 WO2004039829A2 (en) 2004-05-13
WO2004039829A3 true WO2004039829A3 (en) 2004-09-10

Family

ID=32230300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/005520 WO2004039829A2 (en) 2002-10-29 2003-10-29 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection

Country Status (19)

Country Link
US (3) US7998492B2 (en)
EP (2) EP1556077A2 (en)
JP (1) JP2006515277A (en)
KR (1) KR20050089799A (en)
CN (2) CN1753687A (en)
AT (1) ATE544466T1 (en)
AU (2) AU2003283647B2 (en)
BR (1) BR0315810A (en)
CA (1) CA2503693A1 (en)
DK (1) DK2241325T3 (en)
EA (1) EA008777B1 (en)
ES (1) ES2381224T3 (en)
HK (1) HK1149894A1 (en)
MX (1) MXPA05004588A (en)
NZ (1) NZ540098A (en)
PT (1) PT2241325E (en)
SI (1) SI2241325T1 (en)
WO (1) WO2004039829A2 (en)
ZA (1) ZA200503511B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE464907T1 (en) 1999-02-17 2010-05-15 Csl Ltd IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en) * 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
ES2307568T3 (en) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh CPG TYPE NUCLEIC ACIDS AND SAME USE METHODS.
CN100334228C (en) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 Cimeric immunomodulatory compounds and methods of using the same
SI1446162T1 (en) 2001-08-17 2009-04-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003247880B2 (en) * 2002-07-03 2010-09-02 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
MXPA05004588A (en) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
JP2007524615A (en) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー Low molecular weight Toll-like receptor (TLR) antagonist
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
CA2540949A1 (en) 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP1720568A2 (en) * 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
EP1730281A2 (en) * 2004-04-02 2006-12-13 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
EP1781325A2 (en) * 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2587793A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
CN101160401A (en) * 2005-02-24 2008-04-09 科勒制药集团公司 Immunostimulatory oligonucleotides
US20060213010A1 (en) * 2005-03-22 2006-09-28 Davis David T Mattress sled
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
CA2615626A1 (en) * 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
WO2007088423A2 (en) * 2005-09-16 2007-08-09 Coley Pharmaceutical Gmbh Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
EA013375B1 (en) * 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF SHORT INTERFERING RIBONUCLEIC ACID (siRNA) BY NUCLEOTIDE MODIFICATION
DK1957647T3 (en) 2005-11-25 2015-04-07 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
EP2405002B1 (en) * 2006-02-15 2014-09-24 AdiuTide Pharmaceuticals GmbH Compositions and methods for oligonucleotide formulations
CA2653939C (en) * 2006-05-31 2013-01-22 Toray Industries, Inc. Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
WO2009022215A1 (en) * 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
US20100040576A1 (en) * 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
PT2376107E (en) 2008-12-09 2014-07-25 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
KR20110138354A (en) 2009-03-24 2011-12-27 트랜스진 에스.에이. Biomarker for monitoring patients
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
CN104661664B (en) 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
KR101850319B1 (en) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 Asymmetric auxiliary group
CN104684923B (en) * 2012-07-13 2018-09-28 株式会社新日本科学 Chiral Nuclec acid adjuvants
CN105579582A (en) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP2019513692A (en) * 2016-02-19 2019-05-30 ジェニスフィア・エルエルシー Nucleic acid carriers and therapeutic uses
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
SG11201908909PA (en) * 2017-05-03 2019-10-30 Agency Science Tech & Res Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof
CN109528638B (en) * 2018-12-20 2021-07-06 江西润泽药业有限公司 Ribavirin derivative preparation and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR20010063153A (en) * 1999-12-21 2001-07-09 서유석 Modified phosphodiester CpG oligdeoxynucleotides conjugated with a dG run which have improved immunomodulatory activity and safety
WO2003002065A2 (en) * 2001-06-29 2003-01-09 Chiron Corporation Hcv e1e2 vaccine compositions

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (en) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド Oligonucleotide therapeutic agent and method for producing the same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5591720A (en) 1990-08-16 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
JPH07503615A (en) 1992-02-04 1995-04-20 カイロン　コーポレイション hepatitis drug
US6498147B2 (en) 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US6107062A (en) 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
AU678415B2 (en) 1992-10-05 1997-05-29 Hybridon, Inc. Therapeutic anti-HIV oligonucleotide and pharmaceutical
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
KR960703170A (en) * 1993-06-23 1996-06-19 알버트 디. 프리센. ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTIC USE THEREOF IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION
DE4321946A1 (en) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonic acid esters, process for their preparation and their use
WO1995003407A2 (en) 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US20030109469A1 (en) 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
FR2711670B1 (en) * 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
US6133244A (en) 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2267100T5 (en) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation IMMUNOMODULATING OLIGONUCLEOTIDES.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
JP4359654B2 (en) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Gene expression vector for generating antigen-specific immune response and method of use thereof
US5843770A (en) 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
US6136316A (en) 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
US5854418A (en) 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
DE69721339T2 (en) 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND THEIR APPLICATIONS
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE432348T1 (en) 1997-06-06 2009-06-15 Univ California INHIBITORS OF IMMUNO-STIMULATIVE DNA SEQUENCE ACTIVITY
US6221882B1 (en) 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
EP1007657B1 (en) 1997-08-19 2006-02-08 Idera Pharmaceuticals, Inc. Hiv-specific oligonucleotides and methods of their use
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1100807A1 (en) 1998-07-27 2001-05-23 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
EP1108017A2 (en) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH G-motif oligonucleotides and uses thereof
CA2343522A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
FR2783170B1 (en) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc IMMUNOSTIMULATING EMULSION
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
WO2000020039A1 (en) 1998-10-05 2000-04-13 The Regents Of The University Of California Methods and adjuvants for stimulating mucosal immunity
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
JP2002534438A (en) 1999-01-12 2002-10-15 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム New treatment
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
FR2790955B1 (en) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4642600A (en) 1999-04-15 2000-11-02 Regents Of The University Of California, The Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU4978100A (en) 1999-04-29 2000-11-17 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US6737066B1 (en) 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
AP1891A (en) 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
ATE306938T1 (en) 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa USE OF CPG AS AN ADJUVANT FOR HIV VACCINE
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (en) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
EP1204425B1 (en) 1999-08-19 2009-01-07 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AP2006003503A0 (en) * 1999-09-25 2006-02-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1222281B1 (en) 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
US20070031446A1 (en) 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en) 1999-12-21 2001-07-03 Regents Of The University Of California, The Method for preventing an anaphylactic reaction
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
MXPA02007413A (en) 2000-01-31 2004-07-30 Smithkline Beecham Biolog Novel use.
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6613751B2 (en) 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
AU2001249609A1 (en) 2000-03-28 2001-10-08 Department Of Veterans Affairs Methods for increasing a cytotoxic T lymphocyte response in vivo
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
WO2002018631A2 (en) * 2000-09-01 2002-03-07 Epigenomics Ag Diagnosis of illnesses or predisposition to certain illnesses
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
FR2814958B1 (en) 2000-10-06 2003-03-07 Aventis Pasteur VACCINE COMPOSITION
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
ES2307568T3 (en) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh CPG TYPE NUCLEIC ACIDS AND SAME USE METHODS.
US20030055014A1 (en) * 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
EP1400975A1 (en) * 2001-05-30 2004-03-24 Sony Corporation Reel lock mechanism of tape cassette, and tape cassette
CN100334228C (en) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 Cimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) * 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003012061A2 (en) 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
JP2005518343A (en) * 2001-08-03 2005-06-23 メダレックス， インク． Novel PGC-1 isoforms and their use to improve use-mediated immunotherapy
SI1446162T1 (en) 2001-08-17 2009-04-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US20030133913A1 (en) 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003027313A2 (en) * 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
CA2461315A1 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
DK1455593T3 (en) 2001-10-06 2013-08-26 Merial Ltd PROCEDURES AND COMPOSITIONS FOR PROMOTING GROWTH AND INJURY IMMUNITY OF YOUNG ANIMALS
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DK1719511T3 (en) 2001-11-16 2009-04-14 Coley Pharm Group Inc N- [4- (4-amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl) butyl] methanesulfonamide, a pharmaceutical composition comprising the same, and use thereof
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
JP2005532315A (en) 2002-05-10 2005-10-27 イネックス ファーマシューティカルズ コーポレイション Methylated immunostimulatory oligonucleotides and methods of use thereof
CA2487452A1 (en) 2002-05-28 2003-12-04 Robinson Ramirez-Pineda A method for generating antigen-presenting cells
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
CN1468957A (en) 2002-07-19 2004-01-21 中国人民解放军第二军医大学 Plasmid used as human therapeutic vaccine adjuvant
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
US20040132063A1 (en) 2002-09-25 2004-07-08 Gierse James K. Antisense modulation of microsomal prostaglandin E2 synthase expression
GB0222953D0 (en) 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
MXPA05004588A (en) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
JP4976653B2 (en) * 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
KR100525321B1 (en) 2002-12-13 2005-11-02 안웅식 Pharmaceutical composition for prophylaxis and treatment of papillomavirus-derived diseases comprising papillomavirus antigen protein and CpG-oligodeoxynucleotide
JP2006516099A (en) 2002-12-23 2006-06-22 ダイナバックス テクノロジーズ コーポレイション Branched immunomodulatory compounds and methods of using the compounds
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004087049A2 (en) 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
US20040235770A1 (en) 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
EP1631687A2 (en) 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands
EP2356999A1 (en) * 2003-06-17 2011-08-17 Mannkind Corporation Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
JP2007524615A (en) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー Low molecular weight Toll-like receptor (TLR) antagonist
KR20060031607A (en) 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 Packaged virus-like particles
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2005021726A2 (en) 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
US7576068B2 (en) * 2003-09-05 2009-08-18 Anadys Pharmaceuticals, Inc. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
EP1671643A1 (en) 2003-09-08 2006-06-21 Intellectual Property Consulting Inc. Medicinal composition for treating chronic hepatitis c
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
CA2540949A1 (en) 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
EP1720568A2 (en) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
AU2005222909B2 (en) 2004-03-12 2010-03-11 Idera Pharmaceuticals, Inc. Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
EP1730281A2 (en) * 2004-04-02 2006-12-13 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
AU2005326144A1 (en) 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2574090A1 (en) * 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
BRPI0516953A (en) 2004-09-21 2008-09-30 Cytos Biotechnology Ag virus-like particles comprising an ap205 coat protein fusion protein and an antigenic polypeptide
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CN101160401A (en) * 2005-02-24 2008-04-09 科勒制药集团公司 Immunostimulatory oligonucleotides
EP1874325A2 (en) 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
CN1847256B (en) 2005-04-13 2011-06-15 长春华普生物技术有限公司 Antiviral prepn containing both CpG single-strand deoxyoligonucleotide and ribavirin
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007088423A2 (en) 2005-09-16 2007-08-09 Coley Pharmaceutical Gmbh Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
EA013375B1 (en) 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF SHORT INTERFERING RIBONUCLEIC ACID (siRNA) BY NUCLEOTIDE MODIFICATION
BRPI0616770A2 (en) 2005-09-27 2011-06-28 Coley Pharm Gmbh modulation of tlr-mediated immune responses employing adapter oligonucleotides
DK1957647T3 (en) 2005-11-25 2015-04-07 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
AU2006325225B2 (en) * 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2405002B1 (en) * 2006-02-15 2014-09-24 AdiuTide Pharmaceuticals GmbH Compositions and methods for oligonucleotide formulations
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
MX2009003403A (en) 2006-09-27 2009-04-09 Coley Pharm Group Inc Compositions of tlr ligands and antivirals.
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
RU2009115687A (en) 2006-10-26 2010-11-10 Коли Фармасьютикал Гмбх (De) OLIGORIBONUCLEOTIDES AND THEIR APPLICATION
US20090142362A1 (en) 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
AU2007329375A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
US20100285041A1 (en) 2007-05-17 2010-11-11 Eugen Uhlmann Class A Oligonucleotides with Immunostimulatory Potency
CA2687535C (en) * 2007-05-18 2017-08-22 Coley Pharmaceutical Gmbh Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
WO2009143292A2 (en) * 2008-05-21 2009-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR20010063153A (en) * 1999-12-21 2001-07-09 서유석 Modified phosphodiester CpG oligdeoxynucleotides conjugated with a dG run which have improved immunomodulatory activity and safety
WO2003002065A2 (en) * 2001-06-29 2003-01-09 Chiron Corporation Hcv e1e2 vaccine compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200203, Derwent World Patents Index; Class B04, AN 2002-023500, XP002285703 *
DAVIS H L ET AL: "CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 18, March 2000 (2000-03-01), pages 1920 - 1924, XP004190074, ISSN: 0264-410X *
MALANCHERE-BRES E ET AL: "CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice", JOURNAL OF VIROLOGY, vol. 75, no. 14, July 2001 (2001-07-01), pages 6482 - 6491, XP002285701, ISSN: 0022-538X *
WEERATNA RISINI D ET AL: "CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 32, no. 1, December 2001 (2001-12-01), pages 65 - 71, XP002285702, ISSN: 0928-8244 *

Also Published As

Publication number Publication date
SI2241325T1 (en) 2012-05-31
PT2241325E (en) 2012-04-12
DK2241325T3 (en) 2012-04-10
WO2004039829A2 (en) 2004-05-13
ZA200503511B (en) 2006-10-25
CN101948835A (en) 2011-01-19
EP1556077A2 (en) 2005-07-27
EP2241325A1 (en) 2010-10-20
ATE544466T1 (en) 2012-02-15
AU2003283647A1 (en) 2004-05-25
HK1149894A1 (en) 2011-10-21
BR0315810A (en) 2005-09-13
US20110135605A1 (en) 2011-06-09
AU2010203015B2 (en) 2011-08-25
MXPA05004588A (en) 2005-12-14
AU2010203015A1 (en) 2010-08-05
US7998492B2 (en) 2011-08-16
US20060003962A1 (en) 2006-01-05
KR20050089799A (en) 2005-09-08
US20060246035A1 (en) 2006-11-02
CA2503693A1 (en) 2004-05-13
EP2241325B1 (en) 2012-02-08
EA008777B1 (en) 2007-08-31
NZ540098A (en) 2008-09-26
CN1753687A (en) 2006-03-29
EA200500733A1 (en) 2005-12-29
ES2381224T3 (en) 2012-05-24
AU2003283647B2 (en) 2010-04-15
JP2006515277A (en) 2006-05-25
AU2010203015A2 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
WO2004039829A3 (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
IL123467A0 (en) Methods and compositions for the selective modification of nucleic acids
WO2006135434A3 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
WO2002094250A3 (en) Therapeutic uses of lna-modified oligonucleotides in infectious diseases
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2001068103A3 (en) Treatment of herpes infection using immunomodulatory polynucleotide sequences
WO2002092006A3 (en) Nucleic acid-based compounds and methods of use thereof
WO2005002526A3 (en) Method and compositions for treatment of viral infections
ZA200402232B (en) Method for treating hepatitis C virus infection in treatment failure patients.
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2003037265A3 (en) Method of treating viral infections
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
HUP0401659A3 (en) Method for treating hepatitis c virus infection in treatment failure patients
NO20013101L (en) Outer surface proteins, their genes and their use
WO2009082448A3 (en) Modified oligonucleotides for the treatment of hepatitis c infection
ES2195861T3 (en) USE OF (IR, 4S) -4- (6-AMINO-9H-PURIN-9-IL) -2-CICLOPENTEN-1-METHANOL IN VHB.
WO2002003061A3 (en) Method for identifying substances which are suitable to be used for treating virus infections
WO2023034853A3 (en) Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
WO2005001096A8 (en) Vaccines against sars
JPH07233080A (en) Utilization of virus for therapy of aids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003283647

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 168229

Country of ref document: IL

Ref document number: 1-2005-500775

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2503693

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003775627

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004588

Country of ref document: MX

Ref document number: 2004547932

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057007580

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005/03511

Country of ref document: ZA

Ref document number: 200503511

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 540098

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200500724

Country of ref document: VN

Ref document number: 200500733

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1017/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038A5159X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003775627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057007580

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006246035

Country of ref document: US

Ref document number: 10532746

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0315810

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10532746

Country of ref document: US